US coverage of LVADs (left ventricular assist devices) as destination therapy delayed
This article was originally published in Clinica
Executive Summary
The sheer complexity of drafting a coverage decision is reportedly what is holding up Medicare's announcement on whether it intends to cover left ventricular assist devices (LVADs) as destination therapy for beneficiaries with failing hearts who do not qualify for a heart transplant.